3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Conditions
Carcinoma, Non-Small-Cell Lung
451
Melanoma
287
Squamous Cell Carcinoma of Head and Neck
229
Parkinson Disease 4, Autosomal Dominant Lewy Body
188
Neoplasms
180
Triple Negative Breast Neoplasms
162
Breast Neoplasms
161
Neoplasm Metastasis
156
Lung Neoplasms
141
Colorectal Neoplasms
140
Carcinoma, Renal Cell
129
Head and Neck Neoplasms
120
Stomach Neoplasms
103
Ovarian Neoplasms
101
Carcinoma, Transitional Cell
92
Urinary Bladder Neoplasms
80
Pancreatic Neoplasms
80
Endometrial Neoplasms
74
Carcinoma, Hepatocellular
72
Uterine Cervical Neoplasms
63
Esophageal Neoplasms
57
Recurrence
52
Prostatic Neoplasms
48
Sarcoma
43
Carcinoma
42
Small Cell Lung Carcinoma
39
Glioblastoma
39
Carcinoma, Squamous Cell
39
Hodgkin Disease
36
Lymphoma
34
Interventions
Paclitaxel
3
Carboplatin
3
tremelimumab
1
pembrolizumab
1
necitumumab
1
envafolimab
1
durvalumab
1
anlotinib
1
Nivolumab
1
Gemcitabine
1
Endostatins
1
Drug Therapy
1
Cisplatin
1
130-nm albumin-bound paclitaxel
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Interventional
×
Squamous Non-small Cell Lung Cancer
×
pembrolizumab
×
Clear all
NCT07221474
2026-05-28
INTerpath-13
Merck Sharp & Dohme LLC
Phase 2
Recruiting
180 enrolled